Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2151 to 2200 of 8902 results

  1. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

    Health technology evaluations
    In development

  4. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]

    Awaiting development Reference number: GID-TA11936 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Deucravacitinib for treating active Sjogren's syndrome [TSID12342]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Luspatercept for a-thalassemia [TSID12340]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  12. Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

    Health technology evaluations
    In development

  13. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date:  16 February 2027

    NICE guideline
    In development

  14. Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy

    In development Reference number: GID-HTE10086 Expected publication date:  15 September 2026

    Health technology evaluations
    In development

  15. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  23. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  24. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Bictegravir-Lenacapavir for HIV-1 infection [TSID12343]

    Awaiting development Reference number: GID-TA11943 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  29. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]

    Awaiting development Reference number: GID-TA11945 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Sigvotatug vedotin for Non-small-cell lung cancer [TSID12335]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development Reference number: GID-TA11100 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  35. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  36. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  37. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    Awaiting development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    Awaiting development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  45. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  46. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  47. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  48. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  49. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

    Health technology evaluations
    In development